Clinical trial · Interventional
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was stopped due to slow rate of recruitment.
Summary
Brief summary (as posted)
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low Grade B Cell Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VTX-2337 plus radiotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- VTX-2337 plus radiation
- interventionNames
- Drug: VTX-2337 plus radiotherapy
Primary outcomes (1)
- measure
- Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation.
- timeFrame
- Tumor assessment conducted at 12 weeks and every 3-6 months thereafter
- description
- Tumor response was assessed via CT scans of the chest, abdomen, pelvis or other medically appropriate imaging modality to evaluate all areas of disease. Cheson Criteria were used for calculation of response.
Secondary outcomes (1)
- measure
- Assess the Safety and Feasibility of the Combination Regimen.
- timeFrame
- Safety assessed throughout study period.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Major Inclusion Criteria: * low grade B cell lymphoma * 1 or more sites of disease appropriate for intratumoral injection * measurable disease other than the injection site * Performance Status of 1 or better * Adequate bone marrow, renal and hepatic function * No active autoimmune disease or systemic immunosuppressive drugs * Life expectancy \> 4 months Exclusion Criteria: * Known HIV * Known brain metastases * Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK) * Anticoagulation therapy other than 325mg QD ASA * Significant cardiovascular disease * Pregnant or nursing
References
Publications (0)
Data not yet available